Tomić R, Damber J E, Bergman B
Department of Urology, University of Umeå, Sweden.
Eur Urol. 1988;14(1):6-8. doi: 10.1159/000472886.
Eighteen patients with prostatic adenocarcinoma, treated with oestrogen for 45 months or more, were followed-up after withdrawal of oestrogen treatment. Serum concentrations of testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), oestradiol-17 beta, testosterone-oestradiol-binding globulin (TeBg) and prolactin were measured at different intervals between 3 and 42 months after cessation of treatment. Serum testosterone concentrations after cessation of oestrogen treatment were low (range 71.4 +/- 6.3 to 120.8 +/- 23.7 nmol/100ml), whereas the concentrations of LH (range 21.8 +/- 3.6 to 32.6 +/- 9.1 U/1) and FSH (range 31.2 +/- 5.5 to 54.7 +/- 9.5 U/1) were within or higher than the reference range. Prolactin (range 6.0 +/- 85.3 to 7.9 +/- 68.2 micrograms/1) was within the reference range. No significant changes in serum concentrations of testosterone, LH, FSH and prolactin occurred during the follow-up period. The serum concentrations of both oestradiol-17 beta and TeBg, found between 13 and 36 months after oestrogen cessation (range 43.8 +/- 4.6 to 46.2 +/- 5.9 and 64.0 +/- 2.5 to 86.0 +/- 10.0, respectively) were significantly lower than the concentrations found between 3 and 12 months (range 71.9 +/- 10.4 to 99.8 +/- 12.9 and 124.1 +/- 15.5 to 140.2 +/- 13.7, respectively). It is concluded that in patients with prostatic adenocarcinoma, long-term oestrogen treatment causes an irreversible impairment of Leydig cell function and consequently a reduced testosterone secretion after cessation of oestrogen treatment.
18例接受雌激素治疗45个月或更长时间的前列腺腺癌患者，在停用雌激素治疗后进行了随访。在治疗停止后3至42个月的不同时间间隔测量血清睾酮、黄体生成素（LH）、卵泡刺激素（FSH）、雌二醇-17β、睾酮-雌二醇结合球蛋白（TeBg）和催乳素的浓度。停用雌激素治疗后的血清睾酮浓度较低（范围为71.4±6.3至120.8±23.7nmol/100ml），而LH（范围为21.8±3.6至32.6±9.1U/1）和FSH（范围为31.2±5.5至54.7±9.5U/1）的浓度在参考范围内或高于参考范围。催乳素（范围为6.0±85.3至7.9±68.2μg/1）在参考范围内。在随访期间，血清睾酮、LH、FSH和催乳素的浓度没有显著变化。在停用雌激素后13至36个月发现的雌二醇-17β和TeBg的血清浓度（分别为43.8±4.6至46.2±5.9和64.0±2.5至86.0±10.0）显著低于在3至12个月发现的浓度（分别为71.9±10.4至99.8±12.9和124.1±15.5至140.2±13.7）。结论是，在前列腺腺癌患者中，长期雌激素治疗会导致睾丸间质细胞功能的不可逆损害，因此在停用雌激素治疗后睾酮分泌减少。
